Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology.
OBJECTIVE
To evaluate the efficacy and safety of intravitreal triamcinolone in patients with macular oedema of varying aetiology.


METHODS
Two milligrams of intravitreal triamcinolone acetonide was injected into 34 eyes with persistent macular oedema (17 eyes with macula oedema secondary to posterior uveitis, 13 eyes with diabetic retinopathy, and four with pseudophakic macular oedema). Best corrected visual acuity was determined and transfoveal optical coherence tomography performed after 1 week, 1 month, 3 months and 6 months.


RESULTS
Treatment improved visual acuity and subjective visual quality, and reduced foveal thickness in eyes with posterior uveitis and eyes with macular oedema secondary to diabetic retinopathy. Eyes treated for pseudophakic cystoid macular oedema demonstrated no improvement. A total of 32% of patients experienced a significant post-injection increase in intraocular pressure. Endophthalmitis, rhegmatogenous retinal detachment and cataract were absent.


CONCLUSIONS
Intravitreal triamcinolone appears to induce marked a improvement in macular oedema secondary to non-infectious uveitis and diabetic retinopathy.
Sørensen
Torben Lykke
TL
Department of Ophthalmology, University of Copenhagen, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark. torbenls@dadlnet.dk
Haamann
Per
P
Villumsen
Jørgen
J
Larsen
Michael
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003930:Diabetic Retinopathy / Q000150:complications*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D019591:Pseudophakia / Q000150:complications*; D012189:Retrospective Studies; D012449:Safety; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D015866:Uveitis, Posterior / Q000150:complications*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide